Becton Dickinson and Co

Análisis de la acción Becton Dickinson and Co (BDX)

$191.750

-1.994 (-1.04%)Al cierre

Loading chart…
Máximo
195.990
Apertura
194.420
Precio medio ponderado por volumen
192.65
Volumen
1.41M
Capitalización
66.74B
Mínimo
190.210
Importe
272.15M
EV/EBITDA, TTM
12.68

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

www.bd.com

Análisis de IA of Becton Dickinson and Co (BDX)

Comprar

Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.

Recomendaciones de analistas (15)

+0.46% de potencial alcista
Comprar
10 Comprar
5 Mantener
0 Vender
Actual: 191.75
Mínimo
157.00
Promedio
192.64
Máximo
232.00

Barclays

2026-10-07

Precio objetivo

$165

Infraponderar

BofA

2026-08-31

Precio objetivo

$200

Neutral

RBC Capital

2026-08-13

Precio objetivo

$190

Sector Perform

Citi

2026-08-13

Precio objetivo

$208

Comprar

RBC Capital

2026-08-07

Precio objetivo

$180

Sector Perform

Métricas de valoración

El PER previsto actual de Becton Dickinson and Co (BDX) es 13.72, frente a su media de 5 años de 17.19.

PER previsto

Valor razonable
Media 5A P/E
17.19
P/E actual
13.72
Sobrevalorada
20.85
Infravalorada
13.52

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
14.11
EV/EBITDA actual
12.68
Sobrevalorada
16.40
Infravalorada
11.82

Precio/ventas previsto

Valor razonable
Media 5A P/S
3.18
P/S actual
2.67
Sobrevalorada
3.76
Infravalorada
2.59

Escenarios de precio de Alphio AI para BDX

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%BDX

$193.53

Precio del escenario

B

Base

Base · 50%BDX

$172.62

Precio del escenario

B

Bajista

Bajista · 25%BDX

$171.68

Precio del escenario

Ballenas con BDX en cartera

J

John W. Bristol & Co., Inc.

+ Con en carteraBDX

+6.49%

Rentabilidad a 3 meses

V

Veritas Asset Management LLP

+ Con en carteraBDX

+5.30%

Rentabilidad a 3 meses

J

James Hambro & Partners LLP

+ Con en carteraBDX

+4.65%

Rentabilidad a 3 meses

B

Beutel Goodman & Company Ltd.

+ Con en carteraBDX

+4.35%

Rentabilidad a 3 meses

F

Fort Washington Investment Advisors, Inc.

+ Con en carteraBDX

+4.29%

Rentabilidad a 3 meses

G

Guyasuta Investment Advisors, Incorporated

+ Con en carteraBDX

+3.73%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-07 (ET)

08:30:00

BD Reports Positive Nine-Month Results for Revello Vascular Covered Stent

2026-10-06 (ET)

07:00:00

Becton Dickinson Partners with U.S. Government for $19B Manufacturing Expansion

2026-09-21 (ET)

17:00:00

Becton, Dickinson Appoints Arthur Hu as Chief Information Officer

2026-08-12 (ET)

07:00:00

Becton Dickinson Completes Enrollment in PREVENT Clinical Trial

Noticias

Preguntas frecuentes sobre BDX, respondidas por Alphio AI

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.

15 analysts cover BDX: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 192.64.

Comunidad

Más ↗
range_bonder16/9/2026

Beldex @BeldexCoin recently published two research pieces, and I think they are interesting to look at together. One is about age verification: you only need to prove you are over 18, without handing over your birthday, identity, and nationality all at once. At the same time, it checks that the credential signature is real, that the age is actually derived from that birthday, that the same number is locked in the commitment, and that this number is not below 18. In the end, the other party only gets one result: you meet the age requirement. This is still research for now. Beldex Research Labs is next trying Bulletproof to make the proof smaller and push verification cost down further. It has not yet become a ready feature in BChat or the wallet. The other is VRF consensus. Beldex's current PoS already has a layer of random validator selection. What VRF aims to add is verifiable randomness: everyone can later verify whether the result of who got selected followed the rules, while before the draw it is harder to predict in advance who the next batch will be. The team currently places the VRF-based PoS hardfork in Q1 2027. This is also a later upgrade, not something already fully switched over on mainnet now. One is dealing with how much identity information should be exposed, and the other is dealing with how randomness in consensus should be proven. These two research lines at Beldex are actually quite consistent in direction: provide enough information, and avoid exposing extra information as much as possible.

Mostrar más
Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar